Cargando…

Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study

INTRODUCTION: Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Kl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocco, Monica, Montini, Luca, Alessandri, Elisa, Venditti, Mario, Laderchi, Amalia, De Gennaro, Pascale, Raponi, Giammarco, Vitale, Michela, Pietropaoli, Paolo, Antonelli, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056524/
https://www.ncbi.nlm.nih.gov/pubmed/23945197
http://dx.doi.org/10.1186/cc12853
_version_ 1782320835813441536
author Rocco, Monica
Montini, Luca
Alessandri, Elisa
Venditti, Mario
Laderchi, Amalia
De Gennaro, Pascale
Raponi, Giammarco
Vitale, Michela
Pietropaoli, Paolo
Antonelli, Massimo
author_facet Rocco, Monica
Montini, Luca
Alessandri, Elisa
Venditti, Mario
Laderchi, Amalia
De Gennaro, Pascale
Raponi, Giammarco
Vitale, Michela
Pietropaoli, Paolo
Antonelli, Massimo
author_sort Rocco, Monica
collection PubMed
description INTRODUCTION: Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics. METHODS: The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome. RESULTS: The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone. CONCLUSIONS: In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.
format Online
Article
Text
id pubmed-4056524
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40565242014-06-16 Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study Rocco, Monica Montini, Luca Alessandri, Elisa Venditti, Mario Laderchi, Amalia De Gennaro, Pascale Raponi, Giammarco Vitale, Michela Pietropaoli, Paolo Antonelli, Massimo Crit Care Research INTRODUCTION: Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics. METHODS: The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome. RESULTS: The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone. CONCLUSIONS: In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score. BioMed Central 2013 2013-08-14 /pmc/articles/PMC4056524/ /pubmed/23945197 http://dx.doi.org/10.1186/cc12853 Text en Copyright © 2013 Rocco et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Rocco, Monica
Montini, Luca
Alessandri, Elisa
Venditti, Mario
Laderchi, Amalia
De Gennaro, Pascale
Raponi, Giammarco
Vitale, Michela
Pietropaoli, Paolo
Antonelli, Massimo
Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
title Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
title_full Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
title_fullStr Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
title_full_unstemmed Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
title_short Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
title_sort risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056524/
https://www.ncbi.nlm.nih.gov/pubmed/23945197
http://dx.doi.org/10.1186/cc12853
work_keys_str_mv AT roccomonica riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy
AT montiniluca riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy
AT alessandrielisa riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy
AT vendittimario riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy
AT laderchiamalia riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy
AT degennaropascale riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy
AT raponigiammarco riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy
AT vitalemichela riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy
AT pietropaolipaolo riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy
AT antonellimassimo riskfactorsforacutekidneyinjuryincriticallyillpatientsreceivinghighintravenousdosesofcolistinmethanesulfonateandorothernephrotoxicantibioticsaretrospectivecohortstudy